InnovAge (INNV) Q1 2027 Earnings Call Transcript
InnovAge (INNV) reported Q1 2027 revenue of $264.8M, up 12.1% YoY, and adjusted EBITDA of $31.3M, up 75%. The company cited growth in census and profitability, investments in clinical and operational capabilities, and plans for expansion. Management discussed the impact of the V28 Medicare risk adjustment model, noting differences between PACE and Medicare Advantage.
How this was made

The 30-second read
Why it matters
The earnings datapoints (revenue growth, adjusted EBITDA growth, and census increase) support the bull case for operating leverage, while the V28 explanation highlights potential reimbursement pressure and how PACE’s frailty factor and participant mix could mitigate or alter the impact.
Market read
Traders can update positioning based on fresh quarterly performance and the company’s stated view on how V28 may affect PACE reimbursement and margins.
What to watch
The transcript excerpt ends mid-sentence on V28; traders may need the full call for any quantified sensitivity, guidance, or management commentary on timing of reimbursement impacts and mitigation actions.
Background
InnovAge is a PACE provider, and the call addresses its Q1 fiscal 2027 performance and the industry transition to the V28 Medicare risk adjustment model.
Ticker impact
InnovAge reports Q1 fiscal 2027 results and discusses its InnovAge 3.0 strategy plus how V28 Medicare risk adjustment may affect PACE reimbursement.
Shares may see two-sided trading as the market weighs strong Q1 momentum against uncertainty around V28 reimbursement pressure and how PACE’s frailty factor offsets diagnosis-weight changes.
The transcript provides fresh quarterly datapoints (revenue, adjusted EBITDA, census) and a detailed framework for V28 impacts, which can shift expectations for future margins and utilization.
Market effects
PACE providers and Medicare Advantage-adjacent models may see renewed focus on how risk-adjustment methodology changes flow through to margins.
no specific regional catalyst beyond multi-state operating footprint mentioned.
limited, as the story is US Medicare reimbursement mechanics and a single-company earnings call.
Counterpoint
The V28 discussion may not eliminate risk; investors could discount management’s qualitative differences and still price in margin compression if utilization or coding patterns shift.
Key entities
- companyInnovAge
PACE provider reporting Q1 fiscal 2027 results and outlining InnovAge 3.0 growth priorities plus V28 reimbursement implications.
- regulatory_frameworkV28 Medicare risk adjustment model
Medicare risk scoring methodology change that can alter diagnosis weights and reimbursement for Medicare Advantage and related models.


